These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 3852778)

  • 1. Different allotypes of C3 degrade at different rates.
    Kay PH; Natsuume-Sakai S; Hayakawa J; Dawkins RL
    Immunogenetics; 1985; 22(6):563-9. PubMed ID: 3852778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of immunoglobulins in alternative pathway activation by zymosan. II. The effect of IgG on the kinetics of the alternative pathway.
    Schenkein HA; Ruddy S
    J Immunol; 1981 Jan; 126(1):11-5. PubMed ID: 6905857
    [No Abstract]   [Full Text] [Related]  

  • 3. Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3.
    Pangburn MK; Schreiber RD; Müller-Eberhard HJ
    J Exp Med; 1981 Sep; 154(3):856-67. PubMed ID: 6912277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trypanosoma lewisi: restriction of alternative complement pathway C3/C5 convertase activity.
    Sturtevant JE; Balber AE
    Exp Parasitol; 1987 Jun; 63(3):260-71. PubMed ID: 3556206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum.
    Mayes JT; Schreiber RD; Cooper NR
    J Clin Invest; 1984 Jan; 73(1):160-70. PubMed ID: 6418767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the interactions between properdin, the third component of complement (C3), and its physiological activation products.
    Farries TC; Lachmann PJ; Harrison RA
    Biochem J; 1988 May; 252(1):47-54. PubMed ID: 3421908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathways of complement activation in membranoproliferative glomerulonephritis and allograft rejection.
    Fearon DT; Daha MR; Strom TB; Weiler JM; Carpenter CB; Austen KF
    Transplant Proc; 1977 Mar; 9(1):729-39. PubMed ID: 325806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C3 activation by a new factor B-dependent enzyme detected in culture supernatant from guinea-pig peritoneal macrophages.
    Beuscher HU; Brade V
    Immunology; 1986 Aug; 58(4):545-51. PubMed ID: 3089917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of the interaction between properdin and factor B, components of the alternative-pathway C3 convertase of complement.
    Farries TC; Lachmann PJ; Harrison RA
    Biochem J; 1988 Aug; 253(3):667-75. PubMed ID: 3140783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of cleavage of the third component of human complement (C3) by its small cleavage fragment, C3a: inhibition occurs with the classical-pathway, but not the alternative-pathway, C3 convertase.
    Strunk RC; Webster RO
    Mol Immunol; 1985 Jan; 22(1):37-43. PubMed ID: 3871899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional and structural characterization of four mouse monoclonal antibodies to complement C3 with potential therapeutic and diagnostic applications.
    Subías Hidalgo M; Yébenes H; Rodríguez-Gallego C; Martín-Ambrosio A; Domínguez M; Tortajada A; Rodríguez de Córdoba S; Llorca O
    Eur J Immunol; 2017 Mar; 47(3):504-515. PubMed ID: 28083930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library.
    Sahu A; Kay BK; Lambris JD
    J Immunol; 1996 Jul; 157(2):884-91. PubMed ID: 8752942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel C3 mutation causing increased formation of the C3 convertase in familial atypical hemolytic uremic syndrome.
    Sartz L; Olin AI; Kristoffersson AC; Ståhl AL; Johansson ME; Westman K; Fremeaux-Bacchi V; Nilsson-Ekdahl K; Karpman D
    J Immunol; 2012 Feb; 188(4):2030-7. PubMed ID: 22250080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells.
    Pangburn MK; Müller-Eberhard HJ
    Proc Natl Acad Sci U S A; 1978 May; 75(5):2416-20. PubMed ID: 276881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
    Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L
    Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies on the structure of complement C3 and the stability of C3 derived phagocytic ligands C3b/iC3b in SJL/J and BALB/c mice.
    Lynch DM; Kay PH; Papadimitriou JM; Grounds MD
    Eur J Immunogenet; 1993 Feb; 20(1):1-9. PubMed ID: 8443150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Requirements for beta1H globulin and C3b inactivator in the control of the alternative complement pathway in human serum.
    Whaley K; Thompson RA
    Immunology; 1978 Dec; 35(6):1045-9. PubMed ID: 83964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initiation of the alternative complement pathway due to spontaneous hydrolysis of the thioester of C3.
    Pangburn MK; Müller-Eberhard HJ
    Ann N Y Acad Sci; 1983; 421():291-8. PubMed ID: 6586103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formation of high-affinity C5 convertases of the alternative pathway of complement.
    Rawal N; Pangburn M
    J Immunol; 2001 Feb; 166(4):2635-42. PubMed ID: 11160326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of zymosan-induced alternative complement pathway activation by concanavalin A.
    Smith MC; Pensky J; Naff GB
    Infect Immun; 1982 Dec; 38(3):1279-84. PubMed ID: 6924928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.